Food allergy in children with atopic dermatitis is associated with an increased risk for asthma, allergic rhinitis, and ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Regeneron Pharmaceuticals (REGN ... several of which have been shown to co-morbidly occur with CSU, such as atopic dermatitis and asthma – providing patients with one treatment that might ...

Regeneron has leveraged its monoclonal antibody ... Immunology drug Dupixent is seeing very strong, steady growth in atopic dermatitis and asthma, and approvals continue to expend to new ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

The phase 2b trial compared four doses of temtokibart to placebo in 262 adults with moderate to severe atopic dermatitis, the ...

Sanofi SNY and partner Regeneron REGN announced that the FDA ... moderate-to-severe atopic dermatitis, eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease.

Galderma is now facing off against big, established rivals such as Sanofi and Regeneron’s Dupixent for the U.S. atopic dermatitis market. The company is focusing in particular on the effects of ...

Regeneron Pharmaceuticals ... It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $8.22 EPS, expectations were $8.62. Operator: Welcome to the Regeneron ...